The estimated Net Worth of Farmaceutici Sp A Chiesi is at least $19.5 Tisíc dollars as of 3 February 2014. Farmaceutici Chiesi owns over 11,542,313 units of Cortexyme Inc stock worth over $19,500 and over the last 15 years Farmaceutici sold CRTX stock worth over $0.
Farmaceutici has made over 3 trades of the Cortexyme Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Farmaceutici bought 11,542,313 units of CRTX stock worth $109,651,974 on 3 February 2014.
The largest trade Farmaceutici's ever made was buying 11,542,313 units of Cortexyme Inc stock on 3 February 2014 worth over $109,651,974. On average, Farmaceutici trades about 2,165,504 units every 115 days since 2009. As of 3 February 2014 Farmaceutici still owns at least 10,000 units of Cortexyme Inc stock.
You can see the complete history of Farmaceutici Chiesi stock trades at the bottom of the page.
Farmaceutici's mailing address filed with the SEC is VIA PALERMO 26/A, , PARMA, L6, 43122.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi a Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: